Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Acute heart failure (AHF) is a complex condition often requiring aggressive diuresis.
• Loop diuretics like furosemide are standard treatment, but diuretic resistance can occur.
• Optimizing diuretic strategies is crucial for managing fluid overload in AHF.

Purpose of the Study:

• To determine if adding hydrochlorothiazide (HCTZ) to intravenous furosemide enhances diuretic response in AHF patients.
• To assess the safety and efficacy of this combination therapy.

Main Methods:

• A prospective, double-blind, placebo-controlled trial involving 230 AHF patients.
• Patients received intravenous furosemide plus either HCTZ or a placebo.
• Coprimary endpoints included changes in body weight and dyspnea at 72 hours; secondary outcomes assessed diuresis, renal function, electrolytes, and mortality.

Main Results:

• Patients receiving HCTZ showed significantly greater weight loss (2.3 kg vs. 1.5 kg) and 24-hour diuresis (1775 mL vs. 1400 mL) compared to placebo.
• No significant difference was observed in patient-reported dyspnea.
• HCTZ use was associated with a higher incidence of impaired renal function (46.5% vs. 17.2%), but electrolyte disturbances and mortality rates were similar between groups.

Conclusions:

• The addition of hydrochlorothiazide to loop diuretics improves diuretic response in patients with acute heart failure.
• While effective for fluid management, this combination requires careful monitoring for renal function changes.